Madopar LIQ 62.5
Madopar LIQ 62.5 is a medicine authorised by Swissmedic under authorisation number 52377. The authorisation holder is Roche Pharma (Schweiz) AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 24 February 1994 and the authorisation is valid without a time limit. ATC code N04BA02 places the medicine in the group Anti-Parkinson drugs.
| Authorisation number | 52377 |
|---|---|
| Name | Madopar LIQ 62.5 |
| Full name | Madopar LIQ 62.5, Tabletten zur Herstellung einer Suspension zum Einnehmen |
| Authorisation holder | Roche Pharma (Schweiz) AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | N04BA02 |
| First authorisation | 24 February 1994 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Madopar LIQ 62.5, Tabletten zur Herstellung einer Suspension zum Einnehmen | B | 24 February 1994 |
| 2 | Madopar LIQ 125, Tabletten zur Herstellung einer Suspension zum Einnehmen | B | 24 February 1994 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 21 | 100 | Tablette(n) | N04BA02 | 01.08.0. | B |
| 48 | 30 | Tablette(n) | N04BA02 | 01.08.0. | B |
| 56 | 100 | Tablette(n) | N04BA02 | 01.08.0. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Madopar LIQ 62.5 authorised in Switzerland?
Yes. Madopar LIQ 62.5 is authorised by Swissmedic under authorisation number 52377, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Madopar LIQ 62.5 have?
Madopar LIQ 62.5 is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Madopar LIQ 62.5?
The authorisation holder is Roche Pharma (Schweiz) AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.